Today's Healthcare

The graph on this subscribing doctor's computer was updated early this morning by her patient using a new and unique product called the Biosymtec Monitor.

The patient did not have to leave her home, the doctor could see she was doing fine, and was paid for reviewing the graph by the patient's insurance.

The New Normal

The Biosymtec Monitor is used immediately upon waking, before getting out of bed; always used in the home, never in a hospital or clinic.

The rounded tip dual probes are placed comfortably under the tongue, straddling the frenulum, locating the sensing probe in the perfect location.

Touching the button instantly acquires basal metabolic data and other data from the mouth.   Standing and blowing through the Biosymtec Monitor acquires basal pulmonary data.

As soon as the button is released, the algorithmic results are shown on the face of the Biosymtec Monitor, and the data is forwarded to the subscribing patient's smartphone where a graph appears; in this case both are showing that the patient has acquired no infection.

The patient's smartphone automatically transfers the data to the Biosymtec System, making the graph immediately available to the physician who may be anywhere in the world.

On the other hand, if the patient has acquired a respiratory infection (bacterial or viral) the display on the Biosymtec Monitor may look like this, and the graph, sent to the physician, will clearly show, often days in advance of symptoms, that a respiratory infection has been acquired.

The New Healthcare  
  for the New Normal

Remote Patient Monitoring is used for patients of any age and ability and it has emerged to tackle the quadruple aim by providing benefits to patients that include: • Better access to healthcare, • Improved quality of care,
• Peace of mind and daily assurance, • Improved support, education and feedback.   Source: Vivify Health

The Algorithm

Biosymtec is based upon a proprietary algorithm ("Algorithm") capable of detecting respiratory and non-respiratory infections often days before clinical signs such as a fever.   The Algorithm corelates basal metabolic data with a lung function percentage (PEF%). Basal metabolic data is acquired near the sublingual artery and PEF% is measured by blowing through a scroll/turbine configuration.


The Algorithm was developed after the Anthrax biochemical attack in the U.S. and further refined during the SARS epidemic in Asia. Pre-clinical trials using the Algorithm were completed in Hong Kong (5 health clinics) and Tianjin China (Tianjin Haihe Hospital), shortly after the SARS coronavirus epidemic, and an IRB Approved Research Study in Pennsylvania at a church community.   The data from all sites were combined and analyzed, and the accuracy of the Algorithm was determined to be: Sensitivity 96.7% and Specificity 96.8%.

© 2020  Biosymtec Medical, Inc.